Prognostic value of glucosylceramide synthase and P-glycoprotein expression in oral cavity cancer

International Journal of Clinical Oncology

Volumn 21, Issue 5, 2016, Pages 883-889

  Kim, Ji Won ^a   Park, Yangsoon ^a   Roh, Jong Lyel ^a   Cho, Kyung Ja ^a   Choi, Seung Ho ^a   Nam, Soon Yuhl ^a   Kim, Sang Yoon ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Biomarker; Glucosylceramide synthase; Oral cavity cancer; P glycoprotein; Prognosis

Indexed keywords

CERAMIDE GLUCOSYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN; GLUCOSYLTRANSFERASE; TUMOR MARKER;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CERVICAL LYMPH NODE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH CAVITY; MOUTH SQUAMOUS CELL CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; CHEMISTRY; LYMPH NODE; MIDDLE AGED; MOUTH TUMOR; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; SECONDARY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR INVASION; TUMOR RECURRENCE;

BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; GLUCOSYLTRANSFERASES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; P-GLYCOPROTEIN; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 84961779073     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-016-0973-1     Document Type: Article

References (34)

1. Sigel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29
2. Sano D, Myers JN (2007) Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev 26:645–662
3. Murthy V, Agarwal JP, Laskar SG et al (2010) Analysis of prognostic factors in 1180 patients with oral cavity primary cancer treated with definitive or adjuvant radiotherapy. J Cancer Res Ther 6:282–289
4. Kang H, Kiess A, Chung CH (2015) Emerging biomarkers in head and neck cancer in the era of genomics. Nat Rev Clin Oncol 12:11–26
5. da Silva SD, Ferlito A, Takes RP et al (2011) Advances and applications of oral cancer basic research. Oral Oncol 47:783–791
6. Oliveira LR, Ribeiro-Silva A (2011) Prognostic significance of immunohistochemical biomarkers in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 40:298–307
7. Mizutani T, Masuda M, Nakai E et al (2008) Genuine functions of P-glycoprotein (ABCB1). Curr Drug Metab 9:167–174
8. Sikic BI, Fisher GA, Lum BL et al (1997) Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 40(Suppl):S13–S19
9. Sagol O, Yavuzsen T, Oztop I et al (2005) The effect of apoptotic activity, survivin, Ki-67, and P-glycoprotein expression on prognosis in pancreatic carcinoma. Pancreas 30:343–348
10. Wang B, Li XQ, Ma X et al (2008) Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. Am J Hematol 83:795–799
11. Rocco A, Compare D, Liguori E et al (2012) MDR1-P-glycoprotein behaves as an oncofetal protein that promotes cell survival in gastric cancer cells. Lab Invest 92:1407–1418
12. Ralhan R, Swain RK, Agarwal S et al (1999) P-glycoprotein is positively correlated with p53 in human oral pre-malignant and malignant lesions and is associated with poor prognosis. Int J Cancer 84:80–85
13. Li DW, Gao S, Shen B et al (2011) Effect of apoptotic and proliferative indices, P-glycoprotein and survivin expression on prognosis in laryngeal squamous cell carcinoma. Med Oncol 28(Suppl 1):S333–S340
14. Shabbits JA, Mayer LD (2002) P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. Mol Cancer Ther 1:205–213
15. Ichikawa S, Sakiyama H, Suzuki G et al (1996) Expression cloning of a cDNA for human ceramide glucosyltransferase that catalyzes the first glycosylation step of glycosphingolipid synthesis. Proc Natl Acad Sci USA 93:4638–4643
16. Morad SA, Cabot MC (2013) Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer 13:51–65
17. Liu YY, Han TY, Giuliano AE et al (2001) Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 15:719–730
18. Juul N, Szallasi Z, Eklund AC et al (2010) Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol 11:358–365
19. Zhang X, Wu X, Su P et al (2012) Doxorubicin influences the expression of glucosylceramide synthase in invasive ductal breast cancer. PLoS One 7:e48492
20. Sun CC, Zhang Z, Zhang SY et al (2012) Up-regulation of glucosylceramide synthase in urinary bladder neoplasms. Urol Oncol 30:444–449
21. Liu YY, Patwardhan GA, Xie P et al (2011) Glucosylceramide synthase, a factor in modulating drug resistance, is overexpressed in metastatic breast carcinoma. Int J Oncol 39:425–431
22. Gouazé V, Liu YY, Prickett CS et al (2005) Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res 65(9):3861–3867
23. Edge SB, Byrd DR, Compton CC et al (2010) AJCC Cancer Staging Manual, 7th edn. Springer-Verlag, New York, pp 29–40
24. Rabkin D, Chhieng DC, Miller MB et al (1995) P-glycoprotein expression in the squamous cell carcinoma of the tongue base. Laryngoscope 105:1294–1299
25. Warnakulasuriya S, Jia C, Johnson N et al (2000) p53 and P-glycoprotein expression are significant prognostic markers in advanced head and neck cancer treated with chemo/radiotherapy. J Pathol 191:33–38
26. Uematsu T, Hasegawa T, Hiraoka BY et al (2001) Multidrug resistance gene 1 expression in salivary gland adenocarcinomas and oral squamous-cell carcinomas. Int J Cancer 92:187–194
27. Soni S, Pande P, Shukla NK et al (2002) Coexpression of Ets-1 and p53 in oral carcinomas is associated with P-glycoprotein expression and poor prognosis. J Cancer Res Clin Oncol 128:336–342
28. Friedrich RE, Punke C, Reymann A (2004) Expression of multi-drug resistance genes (mdr1, mrp1, bcrp) in primary oral squamous cell carcinoma. In Vivo 18:133–147
29. Larbcharoensub N, Leopairat J, Sirachainan E et al (2008) Association between multidrug resistance-associated protein 1 and poor prognosis in patients with nasopharyngeal carcinoma treated with radiotherapy and concurrent chemotherapy. Hum Pathol 39:837–845
30. Furusaka T, Sasaki CT, Matsuda A et al (2013) Multidrug resistance in mucoepidermoid carcinoma of the parotid gland–immunohistochemical investigations of P-glycoprotein expression. Acta Otolaryngol 133:552–557
31. Warta R, Theile D, Mogler C et al (2014) Association of drug transporter expression with mortality and progression-free survival in stage IV head and neck squamous cell carcinoma. PLoS One 9:e108908
32. Liu YY, Gupta V, Patwardhan GA et al (2010) Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling. Mol Cancer 9:145
33. Fasanaro E, Staffieri C, Cappellesso R et al (2015) Prognostic significance of serine-phosphorylated STAT3 expression in pT1-T2 oral tongue carcinoma. Clin Exp Otorhinolaryngol 8:275–280
34. Lovato A, Lionello M, Staffieri A et al (2015) A higher angiogenin expression is associated with a nonnuclear Maspin location in laryngeal carcinoma. Clin Exp Otorhinolaryngol 8:268–274